Stocktoria
Unicycive Therapeutics, Inc. UNCY
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-17
Unicycive Therapeutics, Inc. statistics & valuation
Market cap$222.7M
P / B7.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -3077.6% | -1898.2% | — |
| Net margin | — | — | -4525.0% | -1898.8% | — |
| FCF margin | — | — | -2710.4% | -1646.0% | — |
| Return on assets | -54.0% | -116.0% | -215.2% | -640.8% | -53.4% |
| Return on equity | -87.9% | -494.3% | 801.9% | 3875.1% | -60.8% |
| Current ratio | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 |
| Revenue growth | — | — | -29.0% | — | — |
Source: SEC EDGAR filings · CIK 0001766140 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.